CD4+Foxp3+ regulatory T cells (Tregs) are the main immune suppressors with subpopulation of inflamed-tissue related memory Tregs (mTregs) and non-related resting Treg (rTregs). Previously, Treg was proposed to be the cause of chronicity of hepatitis B virus (HBV) infection but with controversies. We then investigated the role of mTregs in distinct immune phases of chronic HBV infection, especially the non-inflammatory versus inflammatory phases. It was found mTregs but not rTregs increased only in the inflammatory phase and correlated with serum alanine aminotransferase (ALT) level. These mTregs accumulated in the inflamed liver, expressed significantly higher Tim-3, CCR4, CCR5 and fewer CCR7, and possessed potent suppressive function. These mTregs mainly originated from natural Tregs because of high Helios expression. Hierarchical clustering analysis showed higher frequency of mTreg was concordant with higher serum ALT and galectin-9 levels. Furthermore, galectin-9 could expand mTregs through galectin-9/Tim-3 interaction. In conclusion, increased mTregs are found only in inflammatory phase of chronic HBV infection. Galectin-9, associated with liver inflammation, contributes to the expansion of mTregs through galectin-9/Tim-3 interaction. Therefore, this expansion of mTregs only reflects as an immune regulatory mechanism to limit the on-going liver damages rather than the cause of chronicity of HBV infection.
Chronic HBV infection is a serious global health problem, affecting more than 350 million people worldwide, with potential adverse sequelae like cirrhosis, liver failure and hepatocellular carcinoma1,2. The natural course of chronic HBV infection could be categorized into four distinct phases: the immune tolerant (IT); immune clearance (IC); low replicative (LR); and hepatitis B e antigen (HBeAg)-negative hepatitis (ENH) phases, with different clinical characteristics of viral replication and liver disease progression3. The IT phase is characterized by high serum level of HBV-DNA and hepatitis B s antigen (HBsAg) level but little liver inflammation. On the contrary, rapid liver fibrosis progression is only observed during the IC and ENH disease phases that are characterized with significant liver inflammation3,4. The traditional explanation for the IT phase is lack of efficient HBV-specific CD8+ and CD4+T cell responses and resurgence of these T cell responses initiates the IC phase5,6. However, recent new observations about increased transcript levels of interferon-stimulated genes7 and the less compromised HBV-specific T-cell responses in IT phase than in IC/ENH phases8 have urged a new immune perspective on these four distinct phases. Therefore, a new notion of non-inflammatory (IT and LR) and inflammatory (IC and ENH) phases of chronic HBV infection emphasizing the liver inflammation was proposed6.
On the other hand, regulatory T cells (Tregs) are a specialized T cell population with the ability to suppress immune responses and maintain immunological tolerance9. Previous studies had shown an increased frequency of Tregs in patients with chronic hepatitis B (CHB)10,11 and the depletion of Tregs could increase CD8+T cells activity10,11,12. In addition, the increase of Tregs was associated with reduction of treatment response to pegylated interferon-α and increased risk of hepatocellular carcinoma12. Furthermore, several researchers also proposed these Tregs might be the cause of the chronicity of HBV infection11,13,14, though others believed it only reflected the host’s attempt to protect itself against immune-mediated pathology15. However, almost all the studies were focused on patients with chronic HBV infection in the phases of IC and/or ENH. The role of Tregs in the natural history of chronic HBV infection had not been fully explored.
Recently, Tregs were further divided into resting Tregs (rTregs) and memory Tregs (mTregs) in mouse model. The mTregs could migrate into inflamed tissue to mitigate tissue damage during the heightened responses of pro-inflammatory memory cells16. On the other hand, human Tregs had been grouped into three phenotypic and functional distinct subpopulations according to the expression of CD45RA and FoxP3: CD45RA+Foxp3lo Tregs, CD45RA−Foxp3hi Tregs, and CD45RA−Foxp3lo Tregs17. The last one, lacking the ability to suppress T cell proliferation, was not a suppressor. The first two were potent suppressors. It had been proposed that the CD45RA+Foxp3lo Tregs were corresponding to human counterpart of rTregs and the CD45RA−Foxp3hi Tregs were corresponding to human counterpart of mTregs in mouse16. As for the human disease situation, it had been demonstrated that the rTregs increased but mTregs decreased in patients with systemic lupus erythromatosus17. On the contrary, mTregs increased in patients with sarcoidosis17, colon cancer18,19,20 and hepatocellular carcinoma18. Furthermore, these mTregs, possessing pro-inflammatory chemokine receptors, could migrate to the inflammed tissue and inhibit the immune responses in inflamed tissue18,19.
We therefore investigate the role of Tregs in these four distinct phases of chronic HBV infection in this study, especially considering the non-inflammatory versus inflammatory phases. In addition, we also study the different Tregs including rTregs and mTregs in this scenario.
Baseline demographic and clinical characteristics of the study population
There were totally 124 chronically HBV infected patients and 38 healthy volunteers enrolled into the study. The baseline characteristics of the 162 patients were listed in Table 1. Compatible with the natural history of chronic HBV infection, patients in IT and IC phase were younger than those in LR and ENH phase. More male patients were presented in the IC and ENH phase. Serum HBV DNA and quantitative HBsAg levels were significantly higher in IT and IC phase than LR phase.
The frequency of Tregs of peripheral blood increased only in IC and ENH phases and correlated with serum alanine aminotransferase level
The proportion of Tregs in CD4+ T cells population of peripheral blood was analyzed using the gate shown in Fig. 1a. A higher percentage of Tregs was detected in chronic HBV infected patients compared with healthy volunteers (6.32 ± 2.08% vs. 5.47 ± 1.63%; p = 0.022). There was variability in the frequency of Tregs among the four phases of patients and healthy volunteers (Fig. 1b). In chronic HBV infected patients with HBeAg, the frequency of Tregs increased significantly in IC phase than in IT phase (6.43 ± 2.19% vs. 5.35 ± 1.56%; p = 0.048). In patients negative for HBeAg, the frequency of Tregs increased significantly in ENH phase than in LR phase (7.19 ± 2.39% vs. 5.92 ± 1.59%; p = 0.007). Both the frequency of Tregs in IC and ENH phase was higher than that of the healthy volunteers (N) (IC vs. N; 6.43 ± 2.19% vs. 5.59 ± 1.50%, p = 0.035, and ENH vs. N; 7.19 ± 2.39% vs. 5.59 ± 1.50%, p < 0.001). However, there was no significant difference in the percentage of Tregs between healthy volunteers and CHB patients in IT and LR phases.
In order to determine the factors that influence the frequency of Tregs of peripheral blood in patients with chronic HBV infection, host and viral characteristics of patients including age, gender, serum ALT, HBV-DNA and HBsAg levels and HBeAg status were analyzed using Spearman’s rank correlation analysis. As shown in Fig. 1c, there was a positive linear correlation between circulating Tregs and serum ALT levels (r = 0.21; p = 0.02). However, the frequency of circulating Tregs did not correlate with age, gender, serum HBV-DNA and HBsAg levels, and HBeAg status (p > 0.05). This suggested that this increase of Tregs was associated with amplitude of liver necroinflammation.
The increase of Tregs in inflammatory phase of chronic HBV infection were of thymus-origin and expressed higher CCR5, Ki67 and Tim-3 than healthy volunteers
Further to examine the phenotypically difference on the Tregs, peripheral blood mononuclear cells (PBMCs) from healthy volunteers and chronic HBV infected patients on inflammatory (IC and ENH) phase were analyzed (Fig. 2a).
The increased frequency of Tregs in CHB patients during liver inflammation might arise from the expansion of thymic-derived natural Tregs or the de novo induction from naïve T cells. Helios, a member of the Ikaros transcription factor family, had been demonstrated to be expressed by 100% of CD4+CD8−Foxp3+ thymocytes. Our data showed the proportion of Tregs with positive Helios expression was similar between healthy volunteers and chronic HBV patients (N vs. HBV, 84.0 ± 3.5% vs. 81.0 ± 6.0%; p = 0.36) (Fig. 2b).
Next, we investigated the chemokine receptors for the Treg trafficking and retention in inflammatory site (Fig. 2c). We found that more Tregs in inflammatory phase of chronic HBV infection expressed C-C chemokine receptor 5 (CCR5), which was a proinflammatory chemokine receptor and indicated these Tregs possessed potential to migrate to inflammatory tissue than healthy volunteers (N vs. HBV, 4.6 ± 2.6% vs. 21.4 ± 12.7%; p < 0.001). However, the percentage of C-C chemokine receptor 4 (CCR4) and C-C chemokine receptor 7 (CCR7) expressing Tregs was similar (CCR4, N vs. HBV, 42.5 ± 17.8% vs. 51.0 ± 19.8%; p = 0.22; CCR7, N vs. HBV, 14.1 ± 9.3% vs. 12.3 ± 9.2%; p = 0.19). In addition, a higher percentage of Tregs of CHB patients expressed Ki67, a protein highly expressed in proliferating cells, than the healthy volunteers (N vs. HBV, 7.4 ± 4.1% vs. 15.3 ± 6.8%; p = 0.002). T-cell immunoglobin mucin 3 (Tim-3) had previously been demonstrated as a marker for a subgroup of Tregs that exerted more robust immunosuppressive functions with the tendency to accumulate in the inflammed tissue21,22. Here, we found more CHB patients had a higher proportion of Tim-3 expressing Tregs than healthy volunteers (N vs. HBV, 4.1 ± 2.6% vs. 9.6 ± 9.7%; p = 0.01).
All these data implied that the increased Tregs in patients with chronic HBV infection in IC and ENH phases were possibly from proliferation of the thymus-origin natural Tregs and with potential to migrate to inflamed tissue and more immunosuppressive ability.
Accumulation of Tregs into the liver in patients with chronic HBV infection
The increased frequency of Tregs with higher Ki67 and Tim-3 expression in CHB patients with elevated ALT levels raised the possibility that the inflamed liver might be the site where tissue-prone Tregs accumulated (Fig. 2c). In order to investigate whether Tregs were accumulated in the liver for limiting local inflammation, liver infiltrating lymphocytes were isolated from liver tissue of six CHB patients with serum ALT > 2 upper limit of normal receiving liver biopsy. In comparison with peripheral blood, the proportion of Tregs in total liver infiltrating lymphocytes of liver tissue was significantly increased than those in peripheral blood (14.2 ± 5.5% vs. 5.7 ± 1.8%; p = 0.03) (Fig. 3a). Furthermore, the liver-infiltrating Tregs expressed even higher proportion of Tim-3 than Tregs of the peripheral blood (61.0 ± 7.2% vs. 6.8 ± 3.1%; p = 0.03) (Fig. 3b).
Memory Tregs, not rTregs, increase during IC and ENH phases
Subsequently, we studied the subgroups of Tregs including mTregs and rTregs in patients with chronic HBV infection (Fig. 4a). It was found the frequency of rTregs was similar among different immune phases. However, the frequency of mTregs in IC and ENH phase increased significantly when compared with that of IT and LR phases and healthy individuals (N, IT, IC, LR, and ENH; 1.4 ± 0.5%, 1.5 ± 0.7%, 1.9 ± 0.8%, 1.5 ± 0.6%, and 2.2 ± 0.9%, respectively; p < 0.001) (Fig. 4b). To determine the factors influencing the frequency of mTregs, host and viral parameters were analyzed by spearman rank correlation analysis. As shown in Fig. 4c, mTreg frequency was only correlated with serum ALT levels (r = 0.29; p = 0.001) but not with age, gender, serum HBV-DNA and HBsAg levels, and HBeAg status (P > 0.05).
Furthermore, we analyzed the phenotype of these mTregs. As shown in Fig. 4d, the Ki67 expression on the mTregs was significantly higher in patients with CHB than healthy volunteers (28.8 ± 12.1% vs. 17.0 ± 9.8%; p = 0.02). Interestingly, the proportion of mTregs with positive Helios expression, a marker of thymic Tregs, was similar in CHB patients and health volunteers (HBV vs. N, 88.0 ± 5.3% vs. 88.3 ± 3.5%; p = 0.78).
As for the chemokine receptor expression on mTregs and rTregs in CHB patients, as shown in Fig. 4e, a higher proportion of mTregs expressed CCR4 and CCR5 than rTregs (CCR4, mTreg vs. rTregs, 72.5 ± 22.1% vs. 16.3 ± 11.5%, p < 0.001; CCR5, mTreg vs. rTregs, 32.7 ± 20.0% vs. 17.5 ± 17.8%, p < 0.001). In addition, there was a lower proportion of mTregs with CCR7 expression than rTregs (12.1 ± 6.8% vs. 25.8 ± 20.5%, p < 0.001). These data suggested that the mTreg was the main subgroup of Tregs increased in chronic HBV infection during liver inflammation. Furthermore, mTregs were mainly thymic origin and were highly replicative and possessed prominent potential to migrate to inflammatory site.
Both the mTregs and rTregs possessed similar suppressive ability and inhibited proliferation of CD4+T cells
In order to demonstrate the suppressive ability of these Tregs from CHB patients, we sorted these subgroups of Tregs and evaluated their suppression ability. As shown in Fig. 4f, both rTregs and mTregs could inhibit the CD4+CD25− T cell proliferation in a dose-dependent manner.
The increased mTregs in chronic hepatitis B were related to galectin-9/Tim-3 interaction through the increased serum levels of galectin-9
Next, we determined which mediators could cause the expansion of mTregs. There were two interesting molecule-interactions that involved in the Treg expansion. One was the tumor necrosis factor-α (TNF-α)/tumor necrosis factor receptor type 2 (TNFR2) interaction and another was the Tim-3/galectin-9 interaction. The expression of TNFR2 was higher in mTregs when compared with rTregs in both HBV-infected patients and healthy volunteers (mTreg vs. rTreg in HBV, 81.6 ± 15.6% vs. 46.4 ± 25.3%; p < 0.0001; mTreg vs. rTreg in normal volunteers, 88.8 ± 20.2% vs. 71.4 ± 25.6%; p < 0.0001), though there was no difference between HBV-infected patients and healthy volunteers in terms of the percentage of TNFR2 expressed mTregs (Fig. 5a). We then analyzed the serum TNF-α levels in CHB patients and healthy individuals. The serum TNF-α levels were similar among CHB patients and healthy volunteers and were not related to serum ALT levels in CHB patients (r = −0.019, p = 0.9) (Fig. 5b).
In previous results described above, Tim-3 expression was up-regulated on Tregs and also on mTregs of CHB patients (HBV vs. N, 10.63 ± 12.21% vs. 4.38 ± 4.26%; p < 0.05). However, this difference was not found in rTregs (Fig. 5a). As for the galectin-9, the serum levels of galectin-9 in chronic HBV patients with normal serum ALT were similar with that in healthy volunteers but increased in HBV patients with elevated ALT levels. In addition, the serum levels of galectin-9 in patients with chronic HBV infection were correlated positively with serum ALT levels (r = 0.34, p = 0.006) (Fig. 5c). These findings were concisely displayed via hierarchical clustering by Euclidean distance (Fig. 5d). IC and ENH phase clustered together, with IT and LR phase forming a separate cluster. Clustering based on similarity of serum ALT, galectin-9 and mTreg frequency, it was showed that a higher frequency of mTreg was concordant with high serum ALT and galectin-9 levels. These data indicated galectin-9 play a role in the increment of mTregs in CHB patients in inflammatory phase.
Next we explore whether the mTregs could be expanded through galectin-9/Tim-3 interaction. As shown in Fig. 5e, we found galecitn-9 could expand the mTregs in vitro and this increment could be reversed by anti-Tim-3 mAbs. Taken together, the increased serum levels of galecin-9 during HBV infection contributed to the expansion of mTregs through the galectin-9/Tim-3 interaction.
The role of Tregs in chronic HBV infection, especially for their relationship to the chronicity of HBV infection, is controversial11,19,23. However, all the evidences are mainly derived from CHB patients with liver inflammation. By investigating the Tregs in different phases, including IT, IC, LR and ENH phases, it could possibly decipher the real role of Tregs in chronic HBV infection. Here, we show the Tregs are only increased in the IC and ENH phases but not in the IT and LR phases. In addition, it is the mTregs rather than rTregs that are responsible for this increase in Tregs. We also show these mTregs with potent suppressive ability would accumulate in the inflamed liver and could be expanded through galectin-9/Tim-3 interaction. Furthermore, the increased serum levels of galectin-9 are associated with liver inflammation (ALT levels). Therefore, we conclude that it is the mTregs that are responsible for the increased Tregs in chronic HBV infection. This increase of mTregs is only correlated with liver inflammation and possibly through galectin-9/Tim-3 interaction.
The functional delineation of Foxp3+CD4+T cells into rTregs and mTregs based on CD45RA and FoxP3 expression16,17 had lead to the observations that mTregs were main suppressors in chronic inflammatory disease, sarcoidosis, liver cirrhosis and cancer17,19,24,25. The importance of these mTregs in inflammation is not only they are potent suppressors but also they possess the pro-inflammatory chemokine receptors and migrate into inflamed tissues19,26. In our analysis, the increased frequency of Tregs in patients with CHB is mainly due to the increased mTregs but not the rTregs. Furthermore, this increase of mTregs is only found in patients in the IC and ENH phases but not in the IT and LR phases. In other words, this increase in the mTregs is correlated with liver inflammation that only found in the phases of IC and ENH, so called inflammatory phase of chronic HBV infection6. This inflammation related increase of Tregs, especially the mTregs, could also be deduced from the results that the frequency of mTregs is only correlated with the serum level of ALT but not serum HBV-DNA levels, HBsAg titers, age, gender and HBeAg status. However, in previous reports, frequency of Tregs was shown to be correlated with HBeAg status11, serum HBV viral titer13 but not the serum ALT levels11,13. The possible explanation could be the different patient population enrolled in different studies that cause these discrepancies. In the present study, patients in four different phases were enrolled based on well-defined definition. However, in other studies, only patients with abnormal ALT were enrolled. Recently, an elegant study focused on the T cell functions in CHB patients of different phases also claimed the increase of Tregs was only in IC and ENH phases, compatible to our results27. Therefore, the increased Tregs only found in the inflammatory phases of chronic HBV infection but not in the non-ifnlammatory phase chronic HBV infection have implied the increase of Tregs in chronic HBV infection is only a protective immune response for the liver inflammation but not for the chronicity of HBV infection. Interestingly, recent publication claimed the myeloid-derived suppressor cells increased in the immune tolerance phase of patients with chronic HBV infection and possibly was the cause of chronicity of HBV infection28. This observation reinforces the notion that Tregs are not the cause of chronicity of HBV infection but are responsible for the protection against immune-mediated pathology of liver.
For regulating the immune responses, Tregs would migrate to the inflamed tissue for inhibiting the ongoing inflammation29. In patients with CHB, the Tregs also showed the tissue-migration tendency and accumulated in the inflamed liver as shown in this study and in previous report13. In previous reports, mTregs were the Tregs that could migrate to the inflamed tissue for suppression of immune responses30,31,32. In the present study, these mTregs also express higher levels of pro-inflammatory chemokine receptors like CCR4 and CCR5 but less lymph-node homing chemokine receptor like CCR7. These observations are similar to the mTregs in patients with colon cancer19 and indicate it is a general phenomenon that these mTregs are responsible for suppressing the immune responses in inflamed tissue.
Another interesting issue is why these mTregs could be expanded and associated with liver inflammation. In our previous report, we had shown that the TNF-α could augment proliferation of mTregs through TNF-α/TNFR2 interaction in patients with hepatoma and colon cancer18. Though the surface expression of TNFR2 is higher in mTreg than that of rTreg in patients with CHB, we do not find significant increased serum levels of TNF-α in CHB patients compared with the healthy volunteers. Therefore, the possibility that mTregs a expanded by TNF-α in patients with CHB is not likely.
On the other hand, our results show the increased serum levels of galectin-9 are associated with the increase serum levels of ALT. It is not a surprising result. It had been reported that increased serum levels of galectin-9 were associated with liver inflammation in patients with CHB33 and chronic hepatitis C34. In addition, the galectin-9 could also expand the Tregs as well34,35. In present study, we demonstrate the Tim-3 expression is significantly higher on the mTregs when compared with rTregs. Furthermore, we show galectin-9 could expand the mTregs through galectin-9/Tim-3 interaction. In addition, we also show the relationship among serum levels of ALT, serum levels of galectin-9 and mTregs by hierarchical clustering analysis. Therefore, it is reasonable to claim the increased serum levels of galectin-9 that associated with liver inflammation could in turn expand the mTregs that migrate to the liver to limit the liver immunopathology in patients with CHB.
Another issue is the origin of these mTregs. In our data, we have shown these mTregs had higher Ki-67 expression than rTregs and healthy volunteers. Furthermore, the Helios expression is similar in mTregs between patients with CHB and healthy volunteers. Helios is a member of the Ikaros transcription factor family and is deemed as a marker for the natural Treg population36,37. Therefore, it is more likely that these expanded mTregs are from thymic-derived Treg population rather than HBV-specific Tregs. This observation further re-enforce the idea that these Tregs are not the cause of chronicity of HBV infection but for the protection against liver immune-pathology. However, this observation does not exclude the role of HBV-specific Tregs in the chronicity of HBV infection. It is still possible that these HBV-specific Tregs are a kind of induced Tregs and locate in the Helio-negative Tregs in these patients38.
In summary, increased mTregs are found in patients of CHB with inflammatory phase (IC and ENH) but not with non-inflammatory phase (IT and LC) and would accumulate in the inflamed liver. Galectin-9, which is associated with liver inflammation through galectin-9/Tim-3 interaction, contributes to the expansion of the mTregs that are mainly originated from natural Tregs. Therefore, this expansion of mTregs only reflects as an immune regulatory mechanism to limit the on-going liver damages rather than the cause of chronicity of HBV infection.
Materials and Methods
We prospectively enrolled 124 patients with chronic HBV infection and 38 healthy controls into the study. None of the patients had received antiviral therapy before enrollment in this study and they were divided into four immune phases according to natural course of chronic HBV infection. The first was IT phase, where HBeAg-positive patients had high viral loads (more than 2 × 106 IU/mL) but normal serum ALT levels. The second was IC phase, which was ALT flare (>2 × upper limit of normal) in HBeAg-positive patients1,2. After HBeAg seroconversion, patient entered the third LR phase with sustained normalization of ALT and low viral load (70~80% patients had serum HBV DNA less than 2 × 103 IU/ml)3,39,40. The fourth phase was ENH phase, where 10~20% of these HBeAg-negative patients encountered ALT flare (>2 × upper limit of normal) and high serum HBV-DNA (>2 × 103 IU/ml)41,42,43. Patients with concurrent hepatitis C virus infection, toxic hepatitis, autoimmune hepatitis, primary biliary cirrhosis, or Wilson’s disease were excluded from this study. Patients with evidence of decompensated liver cirrhosis, chronic alcohol abuse, and psychiatric problems were also excluded. Heparinized peripheral blood samples were obtained from the participants. Liver biopsy specimens were obtained by needle puncture. Informed consents were given to all participants before blood donation. The study was performed in accordance with the ethical guidelines of the International Conference on Harmonisation for Good Clinical Practice and has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (99-0489B, 100-1894B & 102-1058B). Informed consent was obtained from all enrolled patients and healthy volumteers.
Isolation of PBMCs and flow cytometric analysis
PBMCs were isolated from heparinized blood samples by Ficoll-Paque plus (Amersham, Uppsala, Sweden) density gradient. After isolation, cells were washed two times with RPMI-1640 (Gibco, Auckland, N.Z.) and prepared for further study. The surface and intracellular stainings were performed using the following fluorochrome-conjugated antibodies: anti-CD4-PerCP, anti-CD45RA-FITC, anti-CCR4-PE, anti-CCR5-PE, anti-CCR7-PE, anti-Ki67-PE (BD Pharmingen, San Diego, CA), anti-Tim3-PE, anti-TNFR2-PE (R&D Systems, Minneapolis, MN), anti-Helios-PE, anti-FoxP3-APC (eBioscience, San Diego, CA). For intracellular staining, cells were fixed and permeabilized using the Human FoxP3 Buffer Set (eBiosciences, San Diego, CA) according to the manufacturer’s instructions. Isotype-matched control antibodies were used to define the positive staining populations. Stained cells were acquired and analyzed using a FACSAria cytometer (Becton Dickinson, San Jose, CA, USA) with FACSDiVa software (BD Biosciences).
Liver biopsy specimen was obtained from six chronic HBV infected patients and was chopped and incubated with collagenase-D (0.1%) (Gibco, Waltham, USA) in RPMI-1640 with 10% fetal bovine serum (Gibco, Grand Island, NY). After incubate and filtered through nylon mesh, cells were suspended in RPMI-1640 and then stained with anti-CD4-PerCP, anti-CD45RA-FITC, anti-Tim3-PE and anti-Foxp3-APC.
Isolation of Tregs
Fresh isolated PBMCs were stained with anti-CD4-PerCP, anti-CD45RA-FITC and anti-CD25-PE antibodies (BD Pharmingen, San Diego, CA). Then CD45RA+CD25lowCD4+T cells (rTregs) and CD45RA−CD25highCD4+T cells (mTregs mTregs) were isolated from PBMCs using a FACSAria (Becton Dickinson) flow cytometer according the manufacturer’s instruction. CD4+CD25− T cells were also collected for further use as well. The purity of sorting was >99%.
Suppression assay of Tregs
Briefly, CD45RA+CD25lowCD4+T cells (rTreg), CD45RA−CD25highCD4+T cells (mTreg) and CD25−CD4+(non-Tregs) T cells were isolated from PBMC by FACSAria (BD Bioscience).
Freshly isolated CD4+CD25−T cells were used as responder cells. Inhibition of proliferation of CD4+CD25−T cells was tested by adding 25% (5,000 cells), 50% (10,000 cells) and 100% (20,000 cells) rTregs or mTregs to 2 × 104 CD4+CD25− T cells in RPMI-1640 medium containing 10% fetal bovine serum. Cells were stimulated with anti-CD3/CD28 (R&D systems, Minneapolis, USA) coated beads (Invetrogen) for 96hrs. After incubation, the cells were pulsed with 1 μCi/well [3 H] thymidine (Perkin Elmer, Boston, USA) and harvested 16 hours later by scintillation counting.
Measurement of serum galectin-9 and TNF-α
Serum levels of galectin-9 of 60 chronic HBV infected patients and 10 healthy controls were measured using a Galectin-9 ELISA Kit (R&D Systems, Minneapolis, USA). 96-well plates were coated with mouse anti-human Galectin-9 in PBS, and blocked by Reagent Diluent. 100 uL of serum or standards in Reagent Diluent, or an appropriate diluent, was added per well and incubated for 2 hours. Sample was detected using biotinylated goat anti-human Galectin-9. Quantification was performed using Streptavidin-conjugated horseradish peroxidase. Substrate Solution was used for color development, and the optical density was determined with a microplate reader at 450 nm. Serum levels of TNF-α of 64 chronic HBV infected patients and 9 healthy controls were measured using a BD Cytometric Bead Array (Becton, Dickinson, and company, San Jose, CA, USA) as manufacturer’s instruction.
In vitro expansion assay
Purified CD4+T cells isolated from PBMCs of 10 patients by Human CD4+T cell Enrichment kit (Stemcell Technologies, Vancouver, BC, Canada) were cultured in triplicate in a concentration of 4 × 105 cells per well in 200 ul RPMI-1640 containing 10% fetal bovine serum. The cells were stimulated with or without 2 ug/ml galectin-9 (PROSPEC, East Brunswick, USA). The anti-Tim-3 antibodies (5 ug/ml) (Biolegend, San Diego, CA) were added into wells before galectin-9 stimulation or not. The cells not stimulated with galectin-9 or anti-Tim-3 mAb were used as control. Then the cells were harvested after 5 days and stained CD4-PerCP, CD45RA-FITC and Foxp3-APC. After staining, the cells were analyzed with a four-color cytometer (FACS-caliber; CELLQuest Pro software, Beckton Dickinson).
The continuous variables were expressed as mean ± standard deviation values. Two-tailed Student’s unpaired t-test or Mann-Whitney U-test was used to evaluate the difference between the two groups where appropriate. Differences between groups of categorical variables were analyzed using chi-square test. One-way analysis of variance with post Hoc comparison Fisher’s least significant difference was performed to evaluate the difference between multiple groups. Correlation between the Tregs and clinical factors were determined by spearman’s rank correlation analysis. Statistical analysis for suppression assay was performed using Linear Mixed-Effect model. Comparison of the expression of Tregs in PBMC and liver from the same individual and analysis of the in vitro expansion assay results were performed using the Wilcoxon signed rank sum test. Hierarchical clustering was performed using Euclidean distance to evaluate the similarity of each factor to one another. A p value < 0.05 was considered statistically significant. The statistical analyses were performed using the SPSS ver. 12.0 software (SPSS Inc., Chicago, USA).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study was supported by the Chang Gung Memory Hospital Research Grant CMRPG2D0311-3, CMRPG2B0352, CMRPG390961-3, CMRPG3C1181 and CMRPG3C1183.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.